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ABSTRACT
Chronic obstructive pulmonary disease (COPD) and lung cancer are devastating 
pulmonary diseases that commonly coexist and present a number of clinical 
challenges. COPD confers a higher risk for lung cancer development, but available 
chemopreventive measures remain rudimentary. Current studies have shown a 
marked benefit of cancer screening in the COPD population, although challenges 
remain, including the common underdiagnosis of COPD. COPD-associated lung cancer 
presents distinct clinical features. Treatment for lung cancer coexisting with COPD is 
challenging as COPD may increase postoperative morbidities and decrease survival. 
In this review, we outline current progress in the understanding of the clinical 
association between COPD and lung cancer, and suggest possible cancer prevention 
strategies in this patient population.
Chronic obstructive pulmonary disease (COPD) 
and lung cancer are both devastating pulmonary diseases 
[1], and they are projected to rank fourth and sixth cause 
of death in the next decades, respectively [2]. COPD 
is generally defined as chronic minimally reversible 
airflow obstruction on the basis of spirometry (post-
bronchodilator forced expiratory volume in 1 second 
[FEV1]/forced vital capacity [FVC] less than 70%) 
[3], but it has now been recognized as a heterogeneous 
group of diseases, encompassing two well-characterized 
phenotypes: chronic bronchitis and emphysema [3]. 
Although many previous studies have investigated the 
role of COPD in the development and prognosis of lung 
cancer, their conflicting results have not been clearly 
understood, and some burgeoning areas of research, such 
as the incorporation of COPD into lung cancer screening 
criteria, still remain as a forum of open discussion.
This review will focus on the clinical epidemiologic 
association between COPD and lung cancer, ranging from 
lung cancer development and screening strategy to its 
treatment and prognosis in the setting of COPD, as well 
as cancer prevention strategies for this patient population 
(Figure 1). 
COPD CONFERS A HIGHER RISK OF 
LUNG CANCER
Evidence on the association between COPD and 
lung cancer development has been extensively observed 
in population-based studies [4, 5], lung cancer screening 
trials [6-8], and case-control studies [9-12]. However, with 
the widespread use of computed tomography (CT), the 
research on the etiologic association has been gradually 
changing from spirometry-defined COPD to CT-diagnosed 
emphysema [13]. This has led to controversy about 
whether airflow obstruction on spirometry, or emphysema 
on CT scan, is the more important manifestation of COPD 
linked to an increased risk of lung cancer. Several studies 
[4-6, 9, 10, 14-16] have investigated the interaction 
between airflow obstruction and emphysema relative to 
lung cancer risk, but their results are still contradictory 
(Table 1). Reasons for these disparities may be threefold. 
Firstly, patient demographics may have residual 
effects even after adjustment. Several studies revealed 
that the magnitude of the COPD lung cancer association is 
influenced by patient’s gender [5, 17], smoking habit [4, 7, 
11] and other respiratory disease [18], where the strength 
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of association increases in women, never-smokers and the 
co-existence with pneumonia. Secondly, the method to 
determine emphysema seems to be important. Automated 
analysis virtually eliminates subjectivity in the estimation 
of emphysema [9, 19], whereas visual assessment detects 
clinically meaningful emphysema and avoids incorrect 
interpretation by computer software [20, 21]. A recent 
meta-analysis showed that the association with lung 
cancer was only significant for visually-determined 
emphysema [22]. Thirdly, variable definitions of airflow 
obstruction can give rise to conflicting results. A ratio of 
FEV1 and FVC of less than 0.7 is generally used to define 
airflow obstruction [10]; however, other indices, such as 
FEV1/FVC under the lower limit of normal criteria, and 
reduction of FEV1% predicted, have also been considered 
indicative of airway obstruction [17, 23, 24]. In addition 
to these three main factors, timing of COPD diagnosis 
[4, 11], degree of airflow obstruction [9, 25] and severity 
of emphysema [6, 20] have also been reported to exert 
a remarkable effect on the significance of the impact of 
COPD and/or emphysema on lung cancer risk. Although 
no solid evidence is available at present to clearly 
distinguish the roles of airflow obstruction and emphysema 
in lung cancer development, it is certain that the highest 
lung cancer risk occurs when airflow obstruction and 
emphysema coexist [10, 14]. Therefore, both airflow 
Table 1: Lung cancer risk according to airflow limitation and emphysema
Study case vs. control
Sex, 
female smoking status
Measurement of emphysema 
and associated lung cancer 
risk, OR (95%CI)
Measurement of 
airflow limitation and 
associated lung cancer 
risk, OR (95%CI)
Schwartz et al. [14] 
(2016, n = 1093)
341 vs. 
752 54.3%
never: 2.8%
ever: 97.2%
emphysema on qCT
-950HU
: 2.66 
(1.80, 3.95)¶
emphysema by radiologist read: 
1.80 (1.35, 2.41)¶
self-reported emphysema: 1.87 
(1.25, 2.79)¶
spirometry FEV1/FVC<0.7: 
1.98 (1.50, 2.61)¶
self-reported COPD: 1.43 
(1.05, 1.94)¶
Wang et al. [15] (2012, 
n = 2201)
1069 vs. 
1132 31.7%
never: 47.7%
ever: 52.3%
self-reported emphysema: 1.92 
(1.31, 2.81)§
self-reported emphysema: 1.55 
(1.03, 2.32)¶
spirometry FEV1/FVC<0.7: 
1.54 (1.21, 1.96)§
spirometry FEV1/FVC<0.7: 
1.29 (1.00, 1.68)¶
Maldanado et al. [9] 
(2010, n = 441)
64 vs. 
377 61.6%
current: 58.0%
former: 42.0%
percent emphysema volume on 
qCT
-900HU
: 1.04 (0.82, 1.33)¶
spirometry FEV1/FVC 
continuous: 1.29 (1.02, 
1.62)¶
spirometry FEV1% 
continuous: 1.15 (1.00, 
1.32)¶
Schwartz et al. [5] 
(2009, n = 1126)
562 vs. 
564 100%
never: 49.2%
ex-smoker: 32.2%
current: 38.6%
self-reported emphysema: 3.21 
(1.60, 6.45)¶
self-reported COPD#: 1.67 
(1.15, 2.41)¶
Koshiol et al. [4] (2009, 
n = 4042)
1934 vs. 
2108 22.4%
never: 20.1%
former: 43.0%
current: 36.9%
self-reported emphysema: 3.8 (2.8, 
5.1)¶
self-reported emphysema: 1.9 (1.4, 
2.7)‡
self-reported COPD#: 4.1 
(3.4, 4.9)¶
self-reported COPD#: 2.5 
(2.0, 3.1)‡
Wilson et al. [6] (2008, 
n = 3638)
99 vs. 
3539 48.6%
current: 60.2%
ex-smoker: 39.8%
emphysema by radiologist read: 
4.39 (2.76, 6.99)§
emphysema by radiologist read: 
3.56 (2.21, 5.73)¶
emphysema by radiologist read: 
3.14 (1.91, 5.15)‡
spirometry FEV1/FVC<0.7: 
2.89 (1.89, 4.43)§
spirometry FEV1/FVC<0.7: 
2.09 (1.33, 3.27)¶
spirometry FEV1/FVC<0.7: 
1.41 (0.87, 2.29)‡
de Torres et al. [10] 
(2007, n = 1166)
23 vs. 
1143 26% former: 100%
emphysema by radiologist read: 
3.33 (1.41, 7.85)§ 
emphysema by radiologist read: 
3.13 (1.32, 7.44)¶
emphysema by radiologist read: 
2.51 (1.01, 6.23)‡
spirometry FEV1/FVC<0.7: 
4.83 (2.05, 11.41)§
spirometry FEV1/FVC<0.7: 
2.89 (1.14, 7.27)¶
spirometry FEV1/FVC<0.7: 
2.10 (0.79, 5.58)‡
Kishi et al. [16] (2002, 
n = 120)
24 vs. 
96 58.3%
former: 45%
current: 55%
percent emphysema volume on 
qCT
-900HU
: 1.1 (0.6, 1.9)¶
spirometry FEV1/FVC 
continuous: 1.4 (1.0, 2.2)¶
spirometry FEV1% 
continuous: 1.2 (1.0, 1.5)¶
OR: odds ratio; CI: confidence interval; FEV1: post-bronchodilator forced expiratory volume in 1 second; FVC: forced vital 
capacity; COPD: chronic obstructive pulmonary disease. 
§unadjusted analysis; ¶adjusted for patient demographics; ‡adjusted for patient demographics, and emphysema or airflow 
limitation, as appropriate. 
# including reports of emphysema, COPD, and/or chronic bronchitis.
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obstruction and emphysema should be regarded as risk 
factors for lung cancer, and as such, could help identify 
individuals who may need active interventions to preempt 
tumorigenesis and target population who may benefit most 
from cancer screening.
LUNG CANCER PREVENTION IN COPD 
PATIENTS
Lung cancer is one of the most common causes of 
death among COPD patients [26], and continued cigarette 
smoking poses an additional lung cancer risk in patients 
with preexisting COPD [27]. So the first priority of lung 
cancer preventive measures is smoking cessation. A 
population-based cohort study with 31-year follow-up 
demonstrated that participants who quit smoking reduced 
their lung cancer risk by 50% [28]. The Lung Health 
Study, which enrolled 5, 887 smokers with asymptomatic 
airflow obstruction (FEV1/FVC ≤70%), further confirmed 
that lung cancer mortality could be improved most by 
smoking cessation [29]. 
Secondhand tobacco smoke (SHS) exposure 
is another important risk factor for lung cancer [30]. 
Henschke and colleagues revealed that emphysema 
increased the risk of lung cancer in never smokers while 
the SHS exposure was an independent indicator of 
emphysema [7]. In addition, Kim and colleagues pooled 
data from 18 case-control studies in the International Lung 
Cancer Consortium [30], and found that, among both ever 
smokers and never smokers, risk of lung cancer increased 
with increasing years of SHS exposure. Therefore, SHS 
exposure should be avoided in COPD patients at the same 
time.
Inhaled corticosteroids (ICS), which are commonly 
prescribed to COPD patients, are now showing a potential 
cancer prevention effect [31]. A nested case-control 
study of patients with COPD demonstrated that regular 
use of ICS was significantly associated with a decreased 
lung cancer risk [32]. Moreover, Parimon and colleagues 
observed a dose-response relationship where higher 
doses of ICS (≥1, 200 ug/d) conferred a risk reduction 
of lung cancer of 61% in COPD patients [33]. Statins 
could attenuate the inflammation in COPD [34, 35] and 
Figure 1: Clinical epidemiologic association between COPD and lung cancer in six areas. The color codes refer to the 
current evidence showing the magnitude of association, where green indicates the association is clearly defined, amber is a debatable issue, 
and red is poorly understood. COPD: chronic obstructive pulmonary disease.
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have potential anticancer effects [36, 37]; however, two 
recent meta-analyses indicated no significant association 
between statin use and the risk of lung cancer [38, 39]. 
For patients with COPD who are already at an increased 
risk of developing lung cancer, Liu and colleagues found 
that COPD patients who used statins exhibited a 63% 
reduced lung cancer risk [40]. Although the data on 
chemopreventive agents (i.e., ICS and statin) at present 
are not as definitive as smoking cessation, it is axiomatic 
that the above-mentioned measures could help not only 
reduce the incidence of lung cancer but also mitigate the 
progression of COPD.
LUNG CANCER SCREENING STRATEGY 
INCORPORATING COPD
Low-dose CT (LDCT) is recommended for lung 
cancer screening by the United States Preventive Services 
Task Force (USPSTF) [41]; however, a recent report 
showed an increasing number of patients with newly 
diagnosed lung cancer falling outside the population 
suggested by USPSTF eligibility criteria [42]. Since 
patients with COPD, regardless of airflow obstruction or 
emphysema, are at higher risk for developing lung cancer 
[8, 12], several studies have targeted this population 
as a candidate for lung cancer screening [8, 23, 43]. 
Lowry and colleagues compared the health benefits of 
different screening programs, and the results showed that 
a program using lower pack-year thresholds (≥1 pack-
year) for individuals with COPD could yield higher life 
expectancy gains than USPSTF using smoking history 
alone [23]. Meanwhile, the detection rate and diagnostic 
precision could be improved by adding CT-detected 
emphysema as a complementary entry criterion to the 
National Lung Screening Trial (NLST) [8]. With respect to 
survival advantage, results from the Danish Lung Cancer 
Screening Trial indicated a favorable effect of screening 
on lung cancer mortality in COPD patients [44]. In order 
to increase the implementation of lung cancer screening 
among COPD patients, however, several aspects should 
be considered. 
(i) Underdiagnosis and misdiagnosis of COPD. 
It has been demonstrated that COPD is remarkably 
under-diagnosed worldwide, with an estimated rate of 
underdiagnosis of 71.2%-81.4% [45, 46]. Misdiagnosis 
of COPD also poses a clinical challenge; 30.4%-40% 
of patients with a prior COPD diagnosis were found to 
have normal lung function on spirometry [47, 48]. As a 
result, recommendation for lung cancer screening in self-
reported COPD would only benefit a limited population, 
leaving four-fifths of cases unrecognized and one-third 
over-treated. Evidence on airflow obstruction and/or 
emphysema are therefore the ideal surrogates in the 
context of lung cancer screening. Young and colleagues 
[49] argued for a widespread use of spirometry screening 
for airflow obstruction in asymptomatic smokers, in an 
attempt to appropriately evaluate the prevalence of COPD 
and detect individuals at an increased risk for lung cancer 
early. Some identified determinants of under-diagnosed 
COPD include male sex, lower level of education, 
being of ethnic minority, and lower comorbidity burden 
[45, 46, 50], while younger age, being overweight, and 
higher levels of comorbidities are risk factors for COPD 
misdiagnosis [50-52]. Therefore, individuals with these 
characteristics should be offered spirometry for a correct 
diagnosis of COPD, which in turn will allow for further 
risk stratification in lung cancer screening [53].
(ii) Further risk assessment. As COPD is identified 
as a driving factor in lung cancer, a refined risk 
stratification among patients with preexisting COPD can 
further improve the cost-effectiveness of CT screening 
and avoid unnecessary radiation exposure [54]. De-Torres 
and colleagues explored risk factors associated with lung 
cancer development in a cohort of outpatients with COPD, 
and identified four independent predictors: baseline age, 
body mass index (BMI), predicted percentage of diffusion 
capacity for carbon monoxide (DLCO%), and GOLD 
stages [25]. Subsequently, the COPD-specific score 
(COPD-LUCSS) was developed to predict lung cancer 
risk for patients with COPD [27]. COPD-LUCSS is 
determined by four parameters: age >60, BMI <25kg/m2, 
pack-years >60, and presence of radiological emphysema, 
with a total range from 0 to 10 points [27]. In comparison 
with low-risk patients (scores 0-6), lung cancer risk 
increased 3.5-fold in the high-risk category (scores 7-10). 
Therefore, COPD patients who are considered at low risk 
of lung cancer may need less frequent screening compared 
to those at high risk, resulting in further reductions in cost 
and screening-related harms. 
(iii) Over-diagnosis of pulmonary nodules. Over-
diagnosis refers to excess lung cancer detected by 
screening that would not affect the patient during their 
lifetime if left untreated [55], which may incur additional 
cost, patient anxiety, and potential morbidities related to 
subsequent diagnostic procedures [56]. It is estimated that 
over-diagnosis accounted for as much as 18.5% of all lung 
cancers detected by LDCT [57]. De-Torres and colleagues 
found that screening in COPD patients resulted in a higher 
detection rate of early-stage lung cancer, without showing 
a significant “histology shift” towards over-diagnosis [43, 
58]. Young and colleagues examined the effect of COPD 
on over-diagnosis and demonstrated that LDCT screening 
in COPD patients yielded a doubling of lung cancer 
incidence without apparent over-diagnosis, whereas in 
non-COPD patients, the stage shift was counterbalanced 
by the excess diagnosis of bronchioloalveolar carcinoma 
[59]. The available data suggest that lung cancer screening 
in individuals with COPD may contribute to a high rate of 
diagnosis of lung cancer at curable stage while minimizing 
over-diagnosis [59, 60].
(iv) Competing causes of mortality/morbidity. 
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The USPSTF recommended that screening should not 
be offered to people who have substantial comorbid 
conditions with limited life expectancy [41]. Sin and 
colleagues reviewed the underlying causes of death 
in COPD patients and reported that the main cause of 
death for mild-to-moderate COPD was lung cancer, 
while for more advanced COPD, respiratory failure was 
the predominant cause [26]. As regards benefit from 
screening, De-Torres and colleagues explored the impact 
of screening on lung cancer mortality in patients with 
mild-to-moderate COPD [43], and the results showed 
that the mortality incidence densities from lung cancer 
were significantly lower in the screening group than in 
the control group (unscreened COPD), justifying active 
screening in patients with milder COPD. However, 
screening patients with more severe COPD may reduce 
cost-effectiveness because the benefits could be surpassed 
by other competing causes of death inherent to COPD 
[61]. In preliminary data from a post-hoc analysis of the 
NLST, it has been shown that the lung cancer specific 
mortality reduction in screening participants with COPD 
was approximately one half that of those without COPD 
(15% vs 28% respectively), suggesting the benefits of CT 
screening in COPD may be diluted by competing causes 
of death [62, 63]. Therefore, the trade-off between the 
potential benefits and harms should be considered by 
participants and their health providers together, when 
considering lung cancer screening in patients with more 
severe COPD [54].
DIFFERENT CLINICAL AND 
MOLECULAR FEATURES OF COPD-
ASSOCIATED LUNG CANCER
Squamous cell carcinoma is more commonly seen 
in the setting of COPD and/or emphysema [25, 64], and 
lung cancer arising in COPD is more likely to be centrally 
located [65]. However, lower emphysema grade tends to 
be associated with central location of lung cancer, while 
higher grade with peripheral location [65]. When the 
extent of emphysema was quantified regionally, a strong 
association was found for cancer being located in the area 
with the highest degree of emphysema [66]. 
In histopathologic analysis, Schiavon and colleagues 
described that COPD-associated adenocarcinoma tended 
to manifest less invasive characteristics, such as increased 
lepidic component and lower cell proliferation, as 
compared to COPD-free adenocarcinoma [67]. However, 
Murakami and colleagues commented that cancer arising 
in emphysema possessed a more aggressive nature [68], 
because the matrix metalloproteinase, which was widely 
up-regulated in emphysematous lungs, was associated 
with the occurrence of lymphovascular invasion and 
postoperative recurrence [68, 69]. Moreover, in post-hoc 
analyses of two CT screening studies, it has been shown 
that smokers with impaired lung function had shorter 
volume doubling times of pulmonary nodules (more 
aggressiveness) and less prevalence of indolent lung 
cancers, suggesting COPD is a useful clinical marker of 
aggressive lung cancer [70-72]. With regard to molecular 
features, several studies found that both EGFR mutations 
and ALK rearrangements were less prevalent in COPD-
associated lung cancer [73, 74], and the presence of EGFR 
mutations was inversely correlated with the severity 
of airflow limitation [73]. In contrast, KRAS mutations 
were independent of COPD status [75, 76]. It is worth 
mentioning, however, that the traits of driver genes 
alternations in lung cancer with COPD could be partly due 
to their associations with patient clinical characteristics 
[75].
TREATMENT FOR LUNG CANCER 
WITH COPD
Major lung resection is the best option for cure in 
lung cancer patients; however, it has been reported that 
about one-third of patients with comorbid COPD may be 
ineligible for surgery for lung cancer that would otherwise 
be technically operable, due to poor physical condition 
[74]. Furthermore, the frequencies of all postoperative 
pulmonary complications (PPCs), including pneumonia 
(10.1%-16.2% in COPD patients following lung cancer 
surgery) [77-79], atelectasis (3.5%-15.4%) [79, 80], 
empyema (2.2%-8.3%) [78], and persistent air leak (12%-
16.2%) [77, 81], were often higher in COPD patients. 
Therefore, an accurate risk assessment in patients with 
lung cancer coexisting with COPD is critically important, 
in order to optimize treatment for these patients.
(i) Identifying risk factors for PPCs. There are only 
a small number of studies to date that have investigated 
risk factors for PPCs in COPD patients undergoing lung 
cancer surgery. Kim and colleagues, in their prospective 
study, reported that the incidence of PPCs was higher 
in patients with COPD but not different between COPD 
grades (FEV1% ≥70% vs. FEV1% <70%) or symptom 
burden (less symptoms vs. more symptoms) [79]. 
Multivariate analysis revealed that lower BMI, reduced 
DLCO%, and operation time were significant predictors 
of PPCs in COPD patients receiving cancer resection. 
In cardiopulmonary exercise testing, Rodrigues and 
colleagues found that the cutoff value of 61% for peak 
oxygen uptake was a significant discriminator between 
COPD patients with and without complications following 
tumor resection [82]. With regard to surgical approach, 
Jeon and colleagues performed a propensity score-
matched analysis and demonstrated that video-assisted 
thoracoscopic surgery in lung cancer patients with 
comorbid COPD could reduce PPCs compared with 
thoracotomy [83]. 
(ii) Effective perioperative management. Medical 
management for COPD, smoking abstinence, and 
pulmonary rehabilitation are three major effective 
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strategies to improve postoperative outcomes [84, 85]. 
Pharmacologic therapy for COPD, such as bronchodilators 
and ICS, can help reduce symptoms, prevent 
exacerbations, and thus increase perioperative safety [79, 
86]. The use of ICS has been justified by a recent study 
that revealed no relationship between the perioperative 
ICS administration and the incidences of PPCs in COPD 
patients receiving pulmonary resection for lung cancer 
[87].
It is clear that smoking cessation should be 
advocated preoperatively. However, the timing of tobacco 
cessation is still controversial. Although a general trend 
was observed for decreasing PPCs with an increase in the 
length of cessation prior to surgery [88], some studies, 
were not as supportive, showing a higher risk for PPCs 
in patients who had quit smoking in the immediate 
preoperative period [89, 90]. Hypothetical explanations 
for this increased risk may relate to the effect of nicotine 
withdrawal and increased sputum volume caused by the 
reduction in irritant-induced coughing, before the recovery 
of ciliary function [91]. Therefore, smoking cessation 
should be encouraged with sufficient duration (2-4 weeks) 
before surgery [85]. 
The effect of preoperative pulmonary rehabilitation 
has now been demonstrated in patients with COPD 
undergoing lung cancer resection [92-94]. Divisi and 
colleagues targeted 27 patients with compromised lung 
function and observed a significant increase in FEV1 (from 
mean FEV1 of 1.14L to 1.65L) after a 4-week preoperative 
pulmonary rehabilitation [94]. Moreover, pulmonary 
rehabilitation is shown to decrease postoperative 
complications as well as length of hospital stay [95]. 
Despite the small sample size included in previous 
studies [94-96], the documented benefits underscore the 
importance of pulmonary rehabilitation for patients with 
advanced COPD prior to lung cancer surgery, to help to 
reduce the function limitations of inoperability.
(iii) Predictors of lung volume reduction effect. 
Patients with lung cancer and COPD receiving cancer 
resection may have a minimal loss, or improvement, in 
postoperative pulmonary function, which is referred to 
as the “lung volume reduction effect” [97, 98]. Various 
methods have been reported to determine potential 
candidates who are more likely to have the functional 
benefit. Korst and colleagues defined the COPD index, a 
scoring system combining preoperative FEV1% predicted 
and FEV1/FVC [99], and found that COPD index <1.0 was 
a good indicator of an improvement of pulmonary function 
following lobectomy. Sekine and colleagues documented 
a greater actual postoperative FEV1 than predicted 
in COPD patients with lobectomy of lower portion 
[100]. Furthermore, quantitative analysis of radiologic 
emphysema could characterize the respiratory dynamics 
underlying the volume reduction effect [101].
(iv) Non-surgical treatment. Patients who are unfit 
for surgery due to poor lung function and/or COPD-related 
systemic comorbidities (such as ischemic cardiac disease) 
could benefit from stereotactic body radiotherapy (SBRT), 
which has been shown as a safe and effective alternative 
treatment for early-stage lung cancer [102]. A recent study 
by Pamla and colleagues reported a 3-year actual local 
control rate of 89% in stage I non-small cell lung cancer 
(NSCLC) patients with concomitant COPD (GOLD class 
III/IV) after SBRT [103], and a subsequent systematic 
review demonstrated comparable outcomes between SBRT 
and surgery in this patient population [103]. The toxicity 
following SBRT was tolerable, and even milder in patients 
with COPD than those with normal lung function [104]. 
Data on the effectiveness of chemotherapy in COPD-
associated lung cancer remain limited, although COPD 
has been reported to increase the risk of chemotherapy-
induced febrile neutropenia [105].
(v) Multidisciplinary treatment (MDT). MDT 
can improve adherence to evidence-based guidelines 
and timeliness of care for lung cancer patients [106]. 
In addition, in the setting of advanced NSCLC, MDT 
has been reportedly associated with a better survival 
rate [107]. Since lung cancer and COPD often coexist, 
pulmonologists could provide prompt diagnosis for 
lung cancer and effective management of pulmonary 
comorbidities [108]. Data from the Surveillance, 
Epidemiology and End Results (SEER) database showed 
that the involvement of pulmonologists in the care of 
patients with early-stage NSCLC and COPD could 
increase surgical resection rate and reduce mortality 
risk [109]. Thus, MDT should be incorporated into the 
treatment of lung cancer concomitant with COPD.
PROGNOSIS OF LUNG CANCER WITH 
COPD
The prognostic significance of COPD in lung 
cancer remains equivocal. Most studies found that COPD 
exerted an unfavorable effect on lung cancer prognosis 
[78, 110, 111], while others did not [112, 113]. Two 
recent meta-analyses indicated COPD as an adverse 
prognostic predictor, but the results suffered from a high 
level of heterogeneity between studies [114, 115]. The 
heterogeneity of effect size is possibly subject to cancer 
stage, treatment modality and status of COPD per se 
[115]. Zhai and colleagues found that coexisting COPD 
was associated with worse survival in patients with 
early-stage NSCLC undergoing surgical resection [110]. 
However, this association was insignificant in the study 
by Izquierdo and colleagues [112], who targeted patients 
with advanced lung cancer (stage IIIB/IV) treated with 
chemotherapy. In terms of COPD grade, there was a more 
apparent decrease in survival for patients with severe 
COPD, but not for those with mild-to-moderate COPD, 
as compared to non-COPD patients following lung cancer 
resection [78, 116]. In addition, quantitative analysis of 
emphysema on CT demonstrated a direct association with 
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lung cancer mortality [21].
Recently, a prognostic model (COPD-LUCSS-
DLCO) was designed to identify patients with COPD 
at high risk of lung cancer death [117]. Patients were 
divided into two risk groups based on a composite score 
determined by patient’s age (2.5 points), BMI (1.5 points), 
pack-year of smoking (1 point), and DLCO% (3 points), 
where the high-risk group (scores 3.5-8) conferred a 2.4-
fold increased risk of death when compared to the low-risk 
group (scores 0-3). In addition, research from the linked 
SEER-Medicare Database demonstrated the addition 
of comorbid COPD to a comprehensive model could 
improve prognostication over similar models using cancer 
information alone [118].
With regard to health-related quality of life, Pompili 
and colleagues performed a propensity score-matched 
analysis among patients undergoing lobectomy for lung 
cancer, and found that patients with COPD experienced 
a comparable postoperative quality of life to matched 
patients without COPD [119]. Pompeo and colleagues 
studied patients who underwent tailored combined surgery 
for both stage I NSCLC and severe emphysema, and 
demonstrated a significant improvement in general health 
domain based on short-form 36 item questionnaire after 
surgery, associated with improvements in dyspnea index 
and exercise capacity [120].
CANCER PREVENTION STRATEGY AND 
FUTURE EFFORTS
Lung cancer prevention strategies should be 
emphasized and encouraged throughout the entire 
disease process. Primary prevention is aimed at limiting 
the incidence of lung cancer. COPD, characterized as 
either airflow obstruction or emphysema, is an important 
predisposing factor for lung cancer development. Thus, a 
primary aim is to control the additional exposures (such as 
smoking and SHS exposure) which contribute to COPD, 
lung cancer, and the progression from COPD to lung 
cancer. The use of chemopreventive agents such as ICS 
and statin remain relatively rudimentary in COPD patients, 
and should be tested in prospective, controlled trials. 
Secondary prevention refers to the early detection of lung 
cancer at a pre-clinical phase, and lung cancer screening 
represents the most important component of this approach. 
The current available evidence shows that lung cancer 
screening in COPD patients confers a high detection rate 
of cancer at early stage (stage shift), and reduces lung 
cancer mortality. Nevertheless, some screening-related 
issues (e.g., underdiagnosis of COPD and potential 
benefit offset) ought to be recognized and discussed in 
the future. With respect to clinical features, lung cancer 
in COPD is quite distinct from that in non-COPD, 
highlighting the demand for a designated screening criteria 
as well as a tailored treatment algorithm in this patient 
population. Tertiary prevention points to the execution 
of treatment and rehabilitation with the principal aim 
of alleviating disability and improving the outcomes of 
illness. Surgery for lung cancer in COPD may have a lung 
volume reduction effect. Precise risk assessment, optimal 
preoperative management (smoking cessation, medical 
treatment for COPD, and pulmonary rehabilitation), 
and MDT care are critically important before surgery. 
Meanwhile, the recognition of the effect of COPD on 
lung cancer prognosis enables refined prognostication 
and thus allows for personalised clinical decision-making. 
Increasing understanding of the relationship between 
COPD and lung cancer will allow the development of 
better cancer preventive strategies and ultimately will 
improve the outcomes of this patient population. 
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